Newsroom | 23617 results

LAS VEGAS--(BUSINESS WIRE)--'Pride on Paradise' Festival Returns Oct. 10 with Plastique Tiara, Adore Delano, Juicy Love Dion, and More...

LOS ANGELES--(BUSINESS WIRE)--On International Day of the Girl, observed annually on Oct. 11, AIDS Healthcare Foundation (AHF) is calling for greater action to ensure girls everywhere have the health, education, protection, and opportunities they need to thrive and reach their full potential. Despite decades of progress, major barriers continue to limit girls’ opportunities. HIV continues to disproportionately affect girls in many parts of the world. In 2025, girls accounted for more than two-t...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Global Chief Scientific and Medical Officer, will participate virtually in a fireside chat at the Piper Sandler Virtual Oncology Symposium, taking place October 15-16, 2026. Details of the event are provided below: Piper Sandler Virtual Oncology Symposium – Fireside Chat Participant: Patrick Soon-Shion...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to deliver a late-breaking oral presentation at The Liver Meeting 2026, the 77th annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting 2026 will take place November 5-9 in Denv...

BALTIMORE--(BUSINESS WIRE)--Pearl Diagnostics (PearlDX), a company pioneering a new generation of non-invasive tests for lung infections, today announced the publication of clinical studies supporting U.S. Food and Drug Administration (FDA) 510(k) clearance of the MycoMEIA® Aspergillus Assay in the peer-reviewed journal Clinical Infectious Diseases. The studies evaluated the urine-based assay as an aid to diagnose invasive aspergillosis (IA), a potentially life-threatening fungal infection in p...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer (CMO), effective October 12, 2026. Dr. Liu will be responsible for leading the clinical development, medical affairs and regulatory affairs functions. “David brings extensive immuno-oncology leadership experience, a strong track record of advancing and securing approvals for innovative cancer therapies and deep expe...

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its third quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also wil...

BILLERICA, Mass. & BEIJING--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, and Innovita Biological Technology Co., Ltd. (SSE: 688253.SH), a leading in vitro diagnostics company in China, today announced regulatory approvals that advance access to the Quanterix SIMOA® technology and neurology biomarker testing in the Chinese market. Initially formed in 2024, the commercialization arrangement combines Quanterix’s ultra-sensitive biomarker de...

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (« MindWalk ») (NASDAQ : HYFT), une entreprise d'IA bio-native, explique aujourd'hui pourquoi la couche ontologique en cours de construction dans l'IA d'entreprise n'atteint pas la fonction biologique, et pourquoi les sciences de la vie exigent une couche de contexte biologique qui leur soit propre. ReefIQ™, la couche de contexte biologique de MindWalk pour les sciences de la vie, fournit ce qu'une ontologie horizontale ne peut offrir : un...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced the phase IIIb CROWN study met its primary endpoint, demonstrating that at six months, long-acting Cabenuva (cabotegravir + rilpivirine [CAB + RPV LA]) achieved superior rates of viral suppression compared with standard-of-care oral antiretroviral therapy (ART) in adults and adolescents living with HIV-1 who had detectable virus when they entered the...